市場調查報告書
商品編碼
1388284
前列腺特異性抗原測試市場 - 按測試類型(初步{總、複雜、免費}、確認性{PCA3、活體組織切片})、按應用(篩檢、監測)、按最終用途(醫院、專科診所、診斷中心) - 2023-2032 年全球預測Prostate-Specific Antigen Test Market - By Test Type (Preliminary {Total, Complex, Free}, Confirmatory {PCA3, Biopsy}), By Application (Screening, Monitoring), By End-use (Hospitals, Specialty Clinics, Diagnostic Centers) - Global Forecast, 2023-2032 |
在向綜合診斷方法(包括驗證性檢測)持續轉變的推動下,前列腺特異性抗原檢測市場規模從 2023 年到 2032 年將以 8.3% 的CAGR擴大。最近,世界各地的醫療保健提供者擴大採用幾種前列腺健康的整體方法,例如將前列腺特異性抗原(PSA)測試整合到更廣泛的診斷策略中。這一轉變強調了早期檢測和個人化治療計劃的重要性,進一步增加了預防性護理中對 PSA 檢測的需求。
隨著對前列腺健康的科學認知不斷進步,研究人員正致力於開發創新療法和藥物。例如,2023 年11 月,根據3 期EMBARK 試驗的結果,安斯泰來製藥和輝瑞獲得美國FDA 批准XTANDI (R)(恩雜魯胺)的補充新藥申請,這是一種有前景的前列腺癌治療選擇患者。因此,隨著此類研發工作的開展,對 PSA 檢測的需求也在增加,因為準確的診斷對於監測治療效果至關重要。
PSA 測試產業分為測試類型、應用、最終用途和區域。
根據測試類型,確認性細分市場的市場規模預計從 2023 年到 2032 年將以 8.7% 的CAGR成長。確認性測試(包括 PCA3 和活體組織切片)對於在檢測到 PSA 水平升高後提供準確和結論性的結果至關重要。對精準醫療和個人化治療計劃的日益重視也增強了前列腺健康診斷中驗證性測試的重要性。此外,醫療保健提供者擴大採用綜合診斷方法將推動該細分市場的成長。
就最終用途而言,醫院領域的前列腺特異性抗原檢測行業預計在 2023 年至 2032 年間將成長 8.3%。由於醫院擁有全面的醫療保健基礎設施,因此成為包括 PSA 檢測在內的診斷程序的主要中心。前列腺相關疾病發生率的上升和人口老化的加劇也導致對常規 PSA 篩檢的需求不斷增加。此外,醫院環境中對早期檢測和癌症預防計劃的重視將促進該細分市場的成長。
從地區來看,亞太地區PSA 檢測行業在2022 年佔據了相當大的收入佔有率,預計到2032 年成長率將超過9%。意識的提高、人口老齡化以及前列腺相關疾病的日益流行正在推動對PSA的需求在該地區進行測試。此外,政府和醫療機構正在積極推動早期檢測和篩檢計畫。診斷程序的技術進步和對男性健康的更加重視也將有助於 PSA 檢測的廣泛採用。
Prostate-Specific Antigen Test Market size is set to expand at 8.3% CAGR from 2023 to 2032, driven by the ongoing shift towards comprehensive diagnostic approaches, including confirmatory tests. Of late, healthcare providers worldwide are increasingly embracing several holistic approaches to prostate health, such as integrating prostate-specific antigen (PSA) testing into broader diagnostic strategies. This shift is emphasizing the significance of early detection and personalized treatment plans, further surging the demand for PSA tests in preventive care.
With rising advances in scientific understanding of prostate health, researchers are focusing on developing innovative therapies and drugs. For instance, in November 2023, based on the outcomes of the Phase 3 EMBARK trial, Astellas Pharma and Pfizer received approval from the U.S. FDA for a supplemental New Drug Application for XTANDI® (enzalutamide), a promising treatment option for prostate cancer patients. The need for PSA tests is hence rising in tandem with such R&D efforts as accurate diagnostics are essential for monitoring treatment efficacy.
The PSA test industry is segmented into test type, application, end-use, and region.
Based on test type, the market size from the confirmatory segment is anticipated to gain 8.7% CAGR from 2023-2032. Confirmatory tests, including PCA3 and biopsy, are essential in providing accurate and conclusive results after an elevated PSA level is detected. The growing emphasis on precision medicine and personalized treatment plans is also enhancing the significance of confirmatory tests in prostate health diagnostics. Moreover, the growing adoption of comprehensive diagnostic approaches by healthcare providers will fuel the segment growth.
In terms of end-use, the prostate-specific antigen test industry from the hospitals segment is expected to witness 8.3% growth rate between 2023 and 2032. Hospitals serve as primary hubs for diagnostic procedures, including PSA testing, due to their comprehensive healthcare infrastructure. The rising incidence of prostate-related disorders and the increasing aging population are also contributing to the increasing demand for routine PSA screenings. Furthermore, the emphasis on early detection and cancer prevention programs within hospital settings will boost the segment growth.
Regionally, the Asia Pacific PSA test industry held sizable revenue share in 2022 and is poised to depict over 9% growth rate through 2032. Increasing awareness, the rising aging population, and the growing prevalence of prostate-related disorders are driving the demand for PSA testing in the region. Additionally, governments and healthcare organizations are actively promoting early detection and screening programs. Technological advancements in diagnostic procedures and the greater emphasis on men health will also contribute to the expanding adoption of PSA tests.